Today, Heron Therapeutics Inc (HRTX) Upgraded to Hold at The Zacks Investment Research

Today, Heron Therapeutics Inc (HRTX) Upgraded to Hold at The Zacks Investment Research

Zacks Investment Research upgraded shares of Heron Therapeutics Inc (NASDAQ:HRTX) from a sell rating to a hold rating in a research report released on Wednesday.

According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “

A number of other analysts have also weighed in on HRTX. Leerink Swann restated a buy rating and set a $33.00 target price on shares of Heron Therapeutics in a report on Sunday, October 2nd. Cantor Fitzgerald restated a buy rating and set a $34.00 target price on shares of Heron Therapeutics in a report on Thursday, November 10th. JMP Securities restated a buy rating on shares of Heron Therapeutics in a report on Friday, September 9th. Brean Capital initiated coverage on Heron Therapeutics in a report on Tuesday, October 4th. They set a buy rating and a $41.00 target price for the company. Finally, Aegis initiated coverage on Heron Therapeutics in a research report on Wednesday, October 26th. They set a buy rating and a $41.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Heron Therapeutics has a consensus rating of Buy and a consensus target price of $41.63.

Heron Therapeutics (NASDAQ:HRTX) opened at 15.20 on Wednesday. The company’s 50-day moving average price is $16.54 and its 200-day moving average price is $18.04. Heron Therapeutics has a 52-week low of $13.95 and a 52-week high of $31.00.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, November 8th. The biotechnology company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by $0.07. On average, analysts predict that Heron Therapeutics will post ($4.50) earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Group LTD increased its position in Heron Therapeutics by 9.0% in the second quarter. BlackRock Group LTD now owns 10,816 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 897 shares during the last quarter. Wells Fargo & Company MN increased its position in Heron Therapeutics by 20.0% in the third quarter. Wells Fargo & Company MN now owns 11,167 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 1,858 shares during the last quarter. Parametric Portfolio Associates LLC purchased a new position in Heron Therapeutics during the second quarter valued at about $213,000. BlackRock Advisors LLC increased its position in Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 1,769 shares during the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in Heron Therapeutics during the third quarter valued at about $266,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Related posts

Leave a Comment